Dasatinib or High-Dose Imatinib for Chronic-Phase Chronic Myeloid Leukemia Resistant to Imatinib at a Dose of 400 to 600 Milligrams Daily Two-Year Follow-Up of a Randomized Phase 2 Study (START-R)

Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77230-1402, USA.
Cancer (Impact Factor: 4.89). 07/2009; 115(18):4136-47. DOI: 10.1002/cncr.24504
Source: PubMed


In patients with chronic-phase chronic myeloid leukemia (CP-CML), imatinib resistance is of increasing importance. Imatinib dose escalation was the main treatment option before dasatinib, which has 325-fold more potent inhibition than imatinib against unmutated Bcr-Abl in vitro. Data with a minimum of 2 years of follow-up were available for the current study of dasatinib and high-dose imatinib in CP-CML resistant to imatinib at daily doses from 400 mg to 600 mg.
A phase 2, open-label study was initiated of 150 patients with imatinib-resistant CP-CML who were randomized (2:1) to receive either dasatinib 70 mg twice daily (n=101) or high-dose imatinib 800 mg (400 mg twice daily; n=49).
At a minimum follow-up of 2 years, dasatinib demonstrated higher rates of complete hematologic response (93% vs 82%; P=.034), major cytogenetic response (MCyR) (53% vs 33%; P=.017), and complete cytogenetic response (44% vs 18%; P=.0025). At 18 months, the MCyR was maintained in 90% of patients on the dasatinib arm and in 74% of patients on the high-dose imatinib arm. Major molecular response rates also were more frequent with dasatinib than with high-dose imatinib (29% vs 12%; P=.028). The estimated progression-free survival also favored dasatinib (unstratified log-rank test; P=.0012).
After 2 years of follow-up, dasatinib demonstrated durable responses and improved response and progression-free survival rates relative to high-dose imatinib.

Download full-text


Available from: Nelson Hamerschlak
    • "Results from a 15-month follow up of a phase 2 dasatinib study (START-C trial; n = 387) in imatinib-resistant/intolerant CP-CML patients showed that dasatinib-induced notable responses, with 91% and 59% patients achieving complete hematologic response (CHR) and MCyR respectively while PFS and OS were 90% and 96%, respectively.[8] In another phase 2 study where imatinib-resistant CP-CML patients were randomized to receive either dasatinib (n = 101) or high dose imatinib, (800 mg/day, n = 49) after a 2-year follow-up dasatinib demonstrated higher rates of CHR (93% vs 82%; P = 0.034), MCyR (53% vs 33%; P = 0.017), CCyR (44% vs 18%; P = 0.0025) and a better PFS (86% vs. 65%; P = 0.0012) than high dose imatinib.[9] Similarly, in a phase 2 nilotinib study in imatinib-resistant/intolerant CP-CML patients (n = 321), rates of MCyR and CCyR after a minimum follow up of 19 months were 59% and 44%, respectively, and the estimated survival at 24 months was 88%.[10] "
    [Show abstract] [Hide abstract]
    ABSTRACT: The prognosis of patients with chronic myeloid leukemia (CML) has changed radically since the advent of imatinib mesylate, a selective inhibitor of BCR-ABL tyrosine kinase. Shortly thereafter, more potent BCR-ABL inhibitors (dasatinib and nilotinib) were introduced for use in patients resistant to or intolerant of imatinib. All three drugs are now approved for initial therapy for chronic phase CML. Response to tyrosine kinase inhibitor (TKI) treatment is assessed with standardized quantitative reverse transcriptase polymerase chain reaction (Q-RTPCR) and/or cytogenetics at 3, 6 and 12 months. Clinical trials have clearly demonstrated that early and deeper cytogenetic and molecular response to TKI therapy is associated with lower rate of disease progression and improved long-term outcomes. In recent times, molecular response as determined by BCR-ABL transcript levels at defined time points is rapidly gaining popularity as a predictive marker for subsequent outcomes in CML. Optimal response is defined as BCR-ABL transcript levels of ≤10% at 3 months, <1% at 6 months, and ≤0.1% from 12 months onward while >10% at 6 months and >1% from 12 months onward define failure. Patients who do not achieve molecular milestones at 3 or 6 months with 3 months being highly predictive are less likely to achieve cytogenetic responses eventually; early identification of such patients who have a low probability of achieving an adequate response are thus candidates for alternative treatment. Review of literature by electronic search of MEDline, Google Scholar was done using keywords and data was identified and systematically evaluated.
    No preview · Article · Mar 2014 · Indian journal of medical and paediatric oncology
  • Source
    • "Spostrzeżenie to ma dużą wartość praktyczną szczególnie w przypadku chorych, u których stan biologiczny nie pozwala na wykonanie alogenicznej transplantacji komórek hemopoetycznych. Podobnie jak w poprzednim, także w tym badaniu tolerancja dazatynibu była dobra, również u osób z objawami uprzedniej nietolerancji IM [41]. Analiza tolerancji dazatynibu w badaniach START wykazała , że skuteczność dazatynibu stosowanego w dawkach 100 mg 1 Â, 50 mg 2 Â, 140 mg 1 Â i 70 mg 2 Â dziennie w fazie przewlekłej jest porównywalna, a dawkowanie 1 Â 100 mg dziennie związane jest z istotnie mniejszą częstością występowania objawów toksyczności terapii, rzadszą koniecznością redukcji dawki i stosowania przerw w leczeniu [42] [43]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Tyrosine kinase inhibitors (TKIs) have dramatically improved the results of therapy of chronic myeloid leukemia. However the management with more potent second generation TKIs (2GTKIs) is required for imatinib-intolerant and imatinib-resistant patients. The frontline use of 2GTKIs results in higher rates of deeper and faster responses than with imatinib, it can enable many patients to qualify for participation in studies of treatment-free remission. The BCR/ABL transcript level at 3 months of TKI treatment has become a new prognostic factor. In this paper the recent clinical results of chronic myeloid leukemia therapy with imatinib in first line and with 2GTKIs in first and second line settings are reviewed, and updated PALG recommendations regarding the diagnosis, standard monitoring procedures, definitions of responses and treatment are presented.
    Full-text · Article · Oct 2013 · Acta haematologica Polonica
  • Source
    • "CCyR rates were 44 and 18 %, respectively (p = 0.0025). Although no formal statistical comparison between the study arms was planned, the data suggested relatively greater efficacy for dasatinib compared with imatinib (Kantarjian et al. 2009a). These responses were also durable, as a pooled analysis (N = 387) of the START-C and START-R studies showed that 90 % of patients achieving a CCyR maintained this level of response after 24 months (Baccarani et al. 2008). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Dasatinib is a dual Abl/Src tyrosine kinase inhibitor (TKI) designed as a prototypic short-acting BCR-ABL-targeted TKI that inhibits BCR-ABL with greater potency compared with imatinib, nilotinib, bosutinib, and ponatinib and has been shown to have potential immunomodulatory effects. Dasatinib is approved for the treatment of all phases of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to prior imatinib treatment and first-line treatment for CML in chronic phase. In this article, the development of dasatinib as a treatment for patients with CML is reviewed. This is a review of the relevant literature regarding dasatinib development in CML (2003-2013). Dasatinib demonstrates efficacy against most BCR-ABL mutations arising during imatinib therapy and is effective in treating patients with imatinib resistance due to other mechanisms. Randomized trial data show that first-line dasatinib provides superior responses compared with imatinib and enables patients to achieve early, deep responses correlated with improved longer-term outcomes. Dasatinib has a generally acceptable safety profile, with most adverse events (AEs) proving manageable and reversible. Cytopenias are commonly observed with dasatinib, and some nonhematologic AEs including pleural effusion have been consistently reported. Dasatinib is an effective treatment option for patients with CML.
    Preview · Article · Aug 2013 · Journal of Cancer Research and Clinical Oncology
Show more